|
1
|
Shimosato Y, Kameya T, Nagai K and Suemasu
K: Squamous cell carcinoma of the thymus. An analysis of eight
cases. Am J Surg Pathol. 1:109–121. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yano M, Sasaki H, Yokoyama T, et al:
Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol.
3:265–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yano M, Sasaki H, Yokoyama T, et al:
Thymic carcinoma with dissemination: a retrospective analysis of
ten patients. Gen Thorac Cardiovasc Surg. 56:335–339. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loehrer PJ Sr, Jiroutek M, Aisner S, et
al: Combined etoposide, ifosfamide, and cisplatin in the treatment
of patients with advanced thymoma and thymic carcinoma: an
intergroup trial. Cancer. 91:2010–2015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koisumi T, Takabayashi Y, Yamagashi S, et
al: Chemotherapy for advanced thymic carcinoma: clinical response
to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC
chemotherapy). Am J Clin Oncol. 25:266–268. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoh K, Goto K, Ishii G, et al: Weekly
chemotherapy with ciaplatin, vincristine, doxorubicin, and
etoposide is an effective treatment for advanced thymic carcinoma.
Cancer. 98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oguri T, Achiwa H, Kato D, et al: Efficacy
of docetaxel as a second-line chemotherapy for thymic carcinoma.
Chemotherapy. 50:279–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Komatsu Y, Koizumi T, Tanabe T, et al:
Salvage chemotherapy with carboplatin and paclitaxel for
cisplatin-resistant thymic carcinoma – three cases. Anticancer Res.
26:4851–4855. 2006.PubMed/NCBI
|
|
9
|
Loehrer P, Yiannoutsos C and Dropcho S: A
phase II trial of pemetrexed in patients with recurrent thymoma or
thymic carcinoma. Am Soc Clin Oncol. 24:70792006.
|
|
10
|
Magois E, Guigay J, Blancard PS, et al:
Multimodal treatment of thymic carcinoma: report of nine cases.
Lung Cancer. 59:126–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tagawa T, Ohta M, Kuwata T, et al: S-1
plus cisplatin chemotherapy with concurrent radiation for
thymicbasaloid carcinoma. J Thorac Oncol. 5:572–573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okuma Y, Shimokawa T, Takagi Y, et al: S-1
is an active anticancer agent for advanced thymic carcinoma. Lung
Cancer. 70:357–363. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koizumi T, Agatsuma T, Komatsu Y and Kubo
K: Successful S-1 monotherapy for chemorefractory thymic carcinoma.
Anticancer Res. 31:299–301. 2011.PubMed/NCBI
|
|
14
|
Totani Y, Saito Y, Hayashi M, et al: A
phase II study of S-1 monotherapy as second-line treatment for
advanced non-small cell lung cancer. Cancer Chemother Pharmacol.
64:1181–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels of for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar
|
|
16
|
Ishihama H, Chida M, Araki O, et al:
Comparison of 5-fluorouracil-related gene expression levels between
adenocarcinomas and squamous cell carcinomas of the lung. Jpn J
Clin Oncol. 39:33–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng Z, Li X, Schell MJ, et al:
Thymidylate synthase in situ protein expression and survival in
stage I nonsmall-cell lung cancer. Cancer. 112:2765–2773. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sasaki H, Fukai I, Kiriyama M, et al:
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA
levels in thymoma. Surg Today. 33:83–88. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnston PG, Lenz HJ and Leichman CG:
Thymidylate synthase gene and protein expression correlate and are
associated with response to 5-fluorouracil in human colorectal and
gastric tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
|
|
20
|
Lenz H, Leichman CG, Danenberg KD, et al:
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a
predictor for primary tumor response and overall survival. J Clin
Oncol. 14:176–182. 1995.PubMed/NCBI
|
|
21
|
Obara S, Yamamoto K, Hosogai N and
Yoshimura Y: Evaluation of TS-1 based treatment and expression of
thymidylate synthase and dihydropyrimidine dehydrogenase on oral
squamous cell carcinoma. Oral Oncol. 41:276–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogiuchi Y, Maruoka Y, Ando T, et al:
Thymidylate synthase, thymidine phosphorylase and orotate
phosphoribosyl transferase levels as predictive factors of
chemotherapy in oral squamous cell carcinoma. Acta Histochem
Cytochem. 41:39–46. 2008. View Article : Google Scholar
|
|
23
|
Chattopadhyay S, Moran RG and Goldman ID:
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and
clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI
|
